{
  "ticker": "LLY",
  "target_date": "2025-07-03",
  "actual_date": "2025-07-03",
  "collected_at": "2025-12-08T11:58:14.507894",
  "price": {
    "open": 777.61,
    "high": 780.69,
    "low": 770.17,
    "close": 777.8167114257812,
    "volume": 1450800,
    "change_1d_pct": 0.18,
    "change_7d_pct": 0.33,
    "change_30d_pct": 4.51
  },
  "technicals": {
    "rsi_14": 37.8,
    "sma_20": 783.63,
    "sma_50": 776.09,
    "macd": 3.49,
    "macd_signal": 5.151,
    "macd_histogram": -1.661,
    "bb_upper": 817.08,
    "bb_lower": 750.17,
    "price_vs_sma20_pct": -0.74,
    "price_vs_sma50_pct": 0.22,
    "volume_ratio": 0.47
  },
  "fundamentals": {
    "market_cap": 892853026816,
    "pe_ratio": 48.798626,
    "forward_pe": 43.95322,
    "price_to_book": 37.49925,
    "price_to_sales": 15.026187,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.43,
    "pct_from_52w_low": 59.67
  },
  "macro": {
    "spy": {
      "price": 623.61,
      "change_1d_pct": 0.79,
      "change_7d_pct": 3.0
    },
    "vix": {
      "level": 16.38,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.35
    },
    "dollar_index": {
      "level": 97.18
    },
    "gold": {
      "price": 3331.6
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report",
      "source": "Yahoo",
      "datetime": 1751567431,
      "summary": "Novo Nordisk A/S\u2019 (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.\u2019s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is ...",
      "url": "https://finnhub.io/api/news?id=78f4dffa541d3e99285e9d7b770d00d307cc699b748b9fbffe8c52de80295109"
    },
    {
      "headline": "Eli Lilly (LLY) Staring at Tremendous Opportunity in Alzheimer Market: RBC Capital Markets",
      "source": "Yahoo",
      "datetime": 1751548766,
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC Capital Markets reiterated that the company\u2019s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock significant value in the Alzheimer\u2019s treatment market. The research firm is o",
      "url": "https://finnhub.io/api/news?id=050cf13f1cf3827b07c178fb844cd0f8aa98ce3c1db7e07f435944238e6419a1"
    },
    {
      "headline": "Pfizer Trades Above 50-Day Average for a Month: Time to Buy?",
      "source": "Yahoo",
      "datetime": 1751546880,
      "summary": "PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.",
      "url": "https://finnhub.io/api/news?id=a20a7d6e358ca1e63f0b7870ff6a32bb9b0c5b0baf6b2371d041d1915b3e3d71"
    },
    {
      "headline": "Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth",
      "source": "Yahoo",
      "datetime": 1751545200,
      "summary": "LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.",
      "url": "https://finnhub.io/api/news?id=360d9ba1a355d3457eb618cc67af06143082c0c6ea67ffb8c98a8ea48247c5bf"
    },
    {
      "headline": "NYLI Winslow Large Cap Growth Fund Q1 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1751499000,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f555296355d4c2b39401f981100486b0e3aac83cd9a6706de47d93ce4af7559b"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}